Gene Biotherapeutics, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2020. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 64 | |
+35.14% | 51.51B | |
-7.43% | 39.03B | |
+35.88% | 38.91B | |
-10.62% | 26.68B | |
+11.63% | 26.13B | |
-17.77% | 19.91B | |
+40.52% | 13.71B | |
+30.70% | 12.38B | |
-3.41% | 11.74B |
- Stock Market
- Equities
- CRXM Stock
- News Gene Biotherapeutics, Inc.
- Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt